Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

202.64
-2.8500-1.39%
Post-market: 202.35-0.2869-0.14%19:44 EDT
Volume:1.89M
Turnover:384.71M
Market Cap:10.26B
PE:32.10
High:204.66
Open:203.59
Low:201.92
Close:205.49
52wk High:217.12
52wk Low:138.79
Shares:50.65M
Float Shares:50.65M
Volume Ratio:1.38
T/O Rate:3.74%
Dividend:0.41
Dividend Rate:0.20%
EPS(TTM):6.31
EPS(LYR):-1.4940
ROE:24.54%
ROA:0.10%
PB:1.26
PE(LYR):-135.64

Loading ...

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

TIPRANKS
·
Aug 31

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Aug 30

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

TIPRANKS
·
Aug 29

Takeda receives FDA approval of NDA for Mimrylo

TIPRANKS
·
Aug 29

Crinetics Shareholders Approve Vertex Acquisition at Special Meeting

TIPRANKS
·
Aug 29

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Amgen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Sector Update: Healthcare

MT Newswires Live
·
Aug 29

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

TIPRANKS
·
Aug 29

Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors

TIPRANKS
·
Aug 29

Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors

TIPRANKS
·
Aug 29

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

Political and General News Events from August 28

Reuters
·
Aug 28

PYC Therapeutics Files 2026 Corporate Governance Statement with ASX

TIPRANKS
·
Aug 28

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Reuters
·
Aug 28

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Reuters
·
Aug 28

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

TIPRANKS
·
Aug 28

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

Reuters
·
Aug 28

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28